Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
The safety profile was consistent with previous reports of amivantamab in EGFR-mutant NSCLC. Amivantamab demonstrated clinically meaningful and durable antitumor activity in participants with METex14 advanced NSCLC, including those who progressed on prior MET therapies.
Authors
- Siyang Qu
- Ki Hyeong Lee (ORCID: https://orcid.org/0000-0002-7830-5950)
- Filippo de Braud (ORCID: https://orcid.org/0000-0003-0103-730X)
- Natasha B. Leighl (ORCID: https://orcid.org/0000-0002-3249-4602)
- Grace Gao (ORCID: https://orcid.org/0000-0001-6109-7406)
- Ji‐Youn Han (ORCID: https://orcid.org/0000-0001-5033-0006)
- Sandrine Hiret (ORCID: https://orcid.org/0000-0002-3789-8171)
- Casilda Llácer Pérez (ORCID: https://orcid.org/0000-0002-4107-5522)
- Meena Thayu
- Jonathan Wade Goldman (ORCID: https://orcid.org/0000-0002-4925-8243)
- Kōichi Goto (ORCID: https://orcid.org/0000-0002-3023-2510)
- Roland E. Knoblauch
- Alexander I. Spira (ORCID: https://orcid.org/0000-0003-1303-0447)
- Robert W. Schnepp (ORCID: https://orcid.org/0000-0003-3217-0381)
- James Chih‐Hsin Yang (ORCID: https://orcid.org/0000-0002-5586-5138)
- Pascale Tomasini (ORCID: https://orcid.org/0000-0002-6474-5912)
- Mahadi Baig (ORCID: https://orcid.org/0009-0002-4456-8055)
- Eric B. Haura (ORCID: https://orcid.org/0000-0003-3114-1909)
- Byoung Chul Cho (ORCID: https://orcid.org/0000-0002-5562-270X)
- Patricia Lorenzini
- Michael Boyer (ORCID: https://orcid.org/0000-0002-0452-2987)
- Catherine A. Shu (ORCID: https://orcid.org/0000-0003-0765-7665)
- Matthew Krebs (ORCID: https://orcid.org/0000-0001-7540-3064)
- Sai‐Hong Ignatius Ou (ORCID: https://orcid.org/0000-0002-1764-4975)
- Zhijie Wang (ORCID: https://orcid.org/0000-0002-7722-4956)
- Jun Zhao (ORCID: https://orcid.org/0000-0003-1464-7158)
- Priya Kim
- Enriqueta Felip
- Joshua C. Curtin
- Rachel E. Sanborn
- Xuesong Lyu
- Makoto Nishio
Institutions
- Centre National de la Recherche Scientifique (FR)
- Johnson & Johnson (United States) (US)
- Inserm (FR)
- University of California, Los Angeles (US)
- National Taiwan University (TW)
- Yonsei University (KR)
- University of California, Irvine (US)
- Aix-Marseille Université (FR)
- Columbia University Irving Medical Center (US)
- Providence Portland Medical Center (US)
- Princess Margaret Cancer Centre (CA)
- Moffitt Cancer Center (US)
- Chris O’Brien Lifehouse (AU)
- Institut de Cancérologie de l'Ouest (FR)
- National Cancer Center (KR)
- Virginia Cancer Specialists (US)
- National Cancer Center Hospital East (JP)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Chungbuk National University Hospital (KR)
- Hôpital de la Timone (FR)
- Japanese Foundation For Cancer Research (JP)
Publication Details
- Journal
- Journal of Thoracic Oncology
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1016/j.jtho.2025.05.012
- Citations
- 12
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 18.22